Krebs Historical Income Statement
KREBSBIO | 104.14 8.79 7.78% |
Historical analysis of Krebs Biochemicals income statement accounts such as Total Revenue of 274.5 M can show how well Krebs Biochemicals and performed in making a profits. Evaluating Krebs Biochemicals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Krebs Biochemicals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Krebs Biochemicals and latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Krebs Biochemicals and is a good buy for the upcoming year.
Krebs |
About Krebs Income Statement Analysis
Krebs Biochemicals and Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Krebs Biochemicals shareholders. The income statement also shows Krebs investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Krebs Biochemicals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Krebs Biochemicals and. It is also known as Krebs Biochemicals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from Krebs Biochemicals and operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Krebs Biochemicals and is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Cost Of Revenue
Cost of Revenue is found on Krebs Biochemicals and income statement and represents the costs associated with goods and services Krebs Biochemicals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Net Interest Income
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.Most accounts from Krebs Biochemicals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Krebs Biochemicals and current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krebs Biochemicals and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. As of now, Krebs Biochemicals' Income Tax Expense is increasing as compared to previous years. The Krebs Biochemicals' current Selling And Marketing Expenses is estimated to increase to about 48.5 M, while Depreciation And Amortization is projected to decrease to under 51.5 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 195.1M | 488.0M | 46.2M | 43.8M | Cost Of Revenue | 737M | 256.8M | 613.0M | 342.2M |
Krebs Biochemicals income statement Correlations
Click cells to compare fundamentals
Krebs Biochemicals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Krebs Biochemicals income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Depreciation And Amortization | 46.8M | 51.2M | 63.0M | 65.6M | 67.7M | 51.5M | |
Interest Expense | 60.0M | 62.8M | 54.4M | 29.7M | 46.9M | 41.6M | |
Selling General Administrative | 8.4M | 6.7M | 11.2M | 8.6M | 6.0M | 5.7M | |
Total Revenue | 235.8M | 386.1M | 529.4M | 521.3M | 504.2M | 274.5M | |
Gross Profit | (93.3M) | (136.3M) | (207.6M) | 264.6M | (108.7M) | (103.3M) | |
Other Operating Expenses | 476.1M | 613.1M | 932.1M | 744.7M | 659.1M | 520.4M | |
Operating Income | (240.3M) | (227.0M) | (402.9M) | (217.2M) | (152.0M) | (159.6M) | |
Ebit | (227.5M) | (220.8M) | (391.4M) | (217.2M) | (150.4M) | (157.9M) | |
Ebitda | (180.7M) | (169.6M) | (328.4M) | (151.6M) | (82.7M) | (86.9M) | |
Cost Of Revenue | 329.1M | 522.3M | 737M | 256.8M | 613.0M | 342.2M | |
Total Operating Expenses | 147.0M | 90.8M | 195.1M | 488.0M | 46.2M | 43.8M | |
Income Before Tax | (288.7M) | (283.6M) | (445.3M) | (246.9M) | (197.3M) | (207.1M) | |
Total Other Income Expense Net | (48.5M) | (111.2M) | (424.9M) | (27.5M) | (45.3M) | (47.6M) | |
Net Income | (288.7M) | (283.6M) | (445.3M) | (246.9M) | (197.3M) | (207.1M) | |
Income Tax Expense | 12.7M | 6.2M | 13.9M | 65.4M | 67.5M | 70.9M | |
Selling And Marketing Expenses | 976K | 47K | 38K | 40.2M | 46.2M | 48.5M | |
Net Income From Continuing Ops | (288.7M) | (283.6M) | (445.3M) | (246.9M) | (197.3M) | (207.1M) | |
Net Income Applicable To Common Shares | (288.7M) | (283.6M) | (445.3M) | (246.9M) | (222.2M) | (233.3M) | |
Interest Income | 51.5M | 62.8M | 3.6M | 29.7M | 34.2M | 40.7M | |
Research Development | 9.7M | 14.7M | 16.4M | 11.3M | 12.7M | 11.1M | |
Net Interest Income | (57.4M) | (62.8M) | (53.9M) | (29.7M) | (46.9M) | (49.2M) | |
Reconciled Depreciation | 46.8M | 51.2M | 63.0M | 65.6M | 67.7M | 59.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Krebs Stock
Krebs Biochemicals and Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Krebs Biochemicals shareholders. The income statement also shows Krebs investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).